Alzheimer’s Society, UK Our research programme

Slides:



Advertisements
Similar presentations
Cancer Research UK strategy and funding Simon Vincent.
Advertisements

Dementia September 2007 You can add your own organisation’s logo alongside the NICE logo DISCLAIMER This slide set is an implementation tool and should.
Monday 1 st July 2013 Health Education England Our Role & Focus on Dementia Professor David Sallah (Clinical Advisor)
Dr. Declan Lyons, Consultant Psychiatrist Dr. Rebecca Quin, Senior Clinical Psychologist.
Healthwatch: Dementia Patient / Customer Experience Briefing to Health and Well-Being Board Janice Horsman Chair Healthwatch Westminster.
1 Developments and progress Dr Martin Freeman GP Clinical Lead for Dementia Services.
Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.
Supporting Carers in General Practice & role of RCGP GP Champions for carers Dr Sachin Gupta GP, Welwyn Garden City RCGP GP Champion for Carers, East of.
How to become a Dementia Friendly Practice All of us want to be treated compassionately and with respect. Patients who have dementia want exactly the same.
Sharing the diagnosis of dementia Alistair Burns Manchester Mental Health and Social Care Trust University of Manchester Manchester Academic Health Science.
‘Dementia & Northern Ireland ’ Report on the Project
João Apóstolo The Portugal Centre for Evidence Based Practice: an affiliate centre of the Joanna Briggs Institute Nursing School of.
Clinical trials with DeNDRoN in the North East Dr Margaret Piggott Data and Communications Manager Dementias and Neurodegenerative.
TBI & Degenerative Conditions. Traumatic Brain Injury (TBI)
Modelling the impact of service innovation in Stroke Care Tanaka Business School: Imperial College. Lead researcher: Dr Benita Cox Background Stroke is.
Patient Empowerment in Chronic Obstructive Pulmonary Disease (COPD) Noreen Baxter Respiratory Nurse Specialist May 2005.
Dementia November This presentation covers: Background Key recommendations Interventions Implementation.
Will we ever have effective treatments for dementia? Robert Howard King’s College London
Dementia Master Class Dr Helen Martin Dr Harry Allen.
Dementia Produced by Wessex LMCs in partnership with: Dr Nicola Decker, GP Alzheimer’s Society.
Achieving improved cancer outcomes- a pathway approach, engaging primary care and partners Kathy Elliott Programme Director – NHS Improving Quality (Delivery.
Dementia Friendly Communities: The National Picture Simon Kitchen, Lead Executive, Dementia Action Alliance.
Serving the people of Cumbria Do not use fonts other than Arial for your presentations Introducing the Cumbria Dementia Pathway.
Welcome Rebecca Wood Chief Executive. Welcome Alzheimer’s Research UK.
GOVERMENT Regulators: CQC HCPC NHS Clinical Commissioning Groups Mental Health Trusts Local Authorities Local Authority Commissioners Social Services Community.
Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.
The CLAHRC Yorkshire and Humber Provision of psychosocial interventions post dementia diagnosis - what can we learn from research and practice? Professor.
LLT dementia1 Dementia - Update and implications for Later Life Training - 1 st steps.
Best Practice Guide: Treatment and care for behavioural and psychological symptoms Clive Ballard, Anne Corbett, Alistair Burns Alzheimer’s Society UK.
2010 NIAMS Scientific Retreat Comparative Effectiveness Research Institute of Medicine Priorities Functional Limitations & Disabilities Endocrinology &
Alzheimer’s disease Platforms for translational research.
Public and patient priorities for research: an international perspective Astrid van der Schot Marco Blom Alzheimer Nederland Glenn Rees Ellen Skladzien.
NOW WHERE HAVE I PUT MY GLASSES? A DISCUSSION AROUND DEMENTIA Dr Marion Overton U3A SCIENCE 19TH JUNE 2015.
1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.
 Our Mission The Canadian Cancer Society is a national, community-based organization of volunteers, whose mission is the.
Measuring Technical Progress and Potential Impact in Real Time Presented at the American Evaluation Association Conference 2009 by Jerald Hage, Wilbur.
From institutionalisation to living well with dementia : a BCU vision Dr Arun Kaimal. MBBS ;MRCPsych Consultant Old Age Psychiatrist and Head of Programme.
AHRQ’s Role in Building Evidence to Advance the Accessibility and Usability of Health IT Tiffani J. Bright, PhD Senior Staff Fellow, Health IT September.
Dementia Care in the UK Professor June Andrews September 2011.
National Dementia Declaration. uk FROM HERE…
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
__________________________________________________________________________________________________
How research helps people with dementia Tom Dening 24 th November 2015.
Improving Cancer Outcomes in Camden Dr Lucia Grun 15 October 2014.
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
Improving dementia care in a challenging sector ________________________________________________________________________________________ alzheimers.org.uk.
Improving Cancer Outcomes in Camden Dr Lucia Grun 19 March 2014.
Alternative approaches to behaviour that challenges Professor Bob Woods Dementia Services Development Centre Bangor University, Wales, UK
Challenging Dementia in Brent Dr Etheldreda Kong Panel: Improving early diagnosis 25 th October 2013.
…Implications for Wales Josie Smith Programme Lead for Substance Misuse, Public Health Wales TOWARDS A HEALTH BASED APPROACH.
Audit of psychotropic medication prescribing in EMI nursing homes in Monmouthshire Dr Pauline Ruth Dr Rui Zheng Dr Arpita Chakraborty Dr Usman Mansoor.
1 ECPC PAPER ON BLADDER CANCER FRANCESCO DE LORENZO Brussels, 20 April 2016.
Dementia 3 rd. edition – August 2011 NICE clinical guideline 42 Implementing the NICE/SCIE guidance.
Dementia Care - a Forward View and a note on the Nottinghamshire Healthcare Strategy Professor Martin Orrell Director, Institute of Mental Health 1.
Dementia NICE clinical guideline 42 Implementing the NICE/SCIE guidance.
The National Dementia Strategy in the East of England Maureen Begley Dementia Programme Manager East of England.
Improvements needed in the care of people living with Dementia.
Dr Rachel Cottam Clinical Lead Community Services Brighton and Hove Clinical Commissioning Group #dementiaconference Gemma Dawson Clinical Commissioning.
Early Intervention in Dementia Bernie Coope Consultant Old Age Psychiatrist/Associate Medical Director/Honorary Senior Lecturer, Worcester Association.
Getting dementia: the housing challenge ________________________________________________________________________________________ alzheimers.org.uk Jeremy.
Dementia NICE quality standard August What this presentation covers Background to quality standards Publication partners Dementia quality standard.
Dementia Alistair Burns. Dementia What is it? Can we diagnose it? Can we treat it? How do we view it? Can we prevent it?
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Dementia Alistair Burns
Using Open Data in Research
Dr Gayan Perera Epidemiologist
BRIGHTLIGHT: from first glow to now – what, why and how
Modifying Disease Course in Alzheimer's Disease
Dementia - challenges today and tomorrow
Dementia: Barriers to accessing quality End of Life Care and Role of Admiral Nurses Chris O’Connor Consultant Admiral Nurse Dementia Fellow   
Presentation transcript:

Alzheimer’s Society, UK Our research programme and the returns from research Dr James Pickett james.pickett@alzheimers.org.uk

The landscape for funding in the EU Joint Programming on Neurodegeneration(JPND)

The landscape for funding in the UK Total spend = ~£64 million Source: Alzheimer’s Research UK annual accounts for 2008-2009

The landscape for funding research in Alzheimer’s Society 2011 – 2012 expenditure £62million 2011 – 2012 expenditure on research ~£2.5million Fund research into cause, care, cure and prevention of dementia Value of portfolio £6million Project grants (24), Fellowships (8), PhD studentships (17) 60% of projects are predominantly animal or cell based projects 40% of projects are human studies (autopsy tissue or patients) 25% of projects involve people with dementia Involvement of carers and people with dementia

Outputs of the research grants programme in the last 12 months Funder of 50 publications liraglutide prevents AD-like neurodegeneration in pre-clinical models of Alzheimer’s disease. Journal of Neuroscience. A review on Alzheimer’s Disease in the leading journal. The Lancet Completion of several high profile clinical trials Donepezil and memantine in moderate to severe AD (DOMINO) New England Journal of medicine, Thursday 8 March. Aromatherapy to treat agitation in dementia Impact beyond publication New referral service for people who are Deaf with cognitive complaints Antipsychotics –development of a best-practice guide with The Department of Health Development online training resources for GPs on the management of dementia and behavioural symptoms.

Impact of research 1989 - 2011 ‘…it takes an average of 17 years for only 14 percent of scientific discoveries to become standard treatment in the community…’ Trochim et al, NIH report

Impact of research 1989 - 2011 £18,800,000

Impact of research 1989 - 2011

Impact of research 1989 - 2011 Knowledge generation

Impact of research 1989 - 2011 Knowledge generation 2010 impact factor No of pubs 0 to 4 125 4 to 7 50 7 to 10 21 10+ 15 £80,000 per publication

Impact of research 1989 - 2011 Knowledge generation Have had an impact in research into cause, care, cure and prevention of dementia: Tau biology Important contributions to the field. Diagnosis Advances in MRI, blood biomarkers and improving diagnosis by GPs Management of behavioural symptoms FITS trial, CALM-AD

Impact of research 1989 - 2011 Developing leaders in dementia research 36 research fellowships 20 PhD studentships 70 per cent of Alzheimer’s Society research fellows have remained active in dementia research. 60 per cent of our research fellows now hold tenured positions in universities and research institutes.

Impact of research 1989 - 2011 Tangible improvements for people with dementia and their carers A standard neuroimaging approach Detection of brain atrophy by MRI is now a recommended approach for diagnosing early changes in dementia and is increasingly beginning to be used in clinical settings. ‘Magnetic resonance imaging (MRI) is the preferred modality to assist with early diagnosis and detect subcortical vascular changes.’ National Clinical guideline on supporting people with dementia and their carers in health and social care Access to cholinesterase inhibitors in the UK Alzheimer’s Society commissioned research that looked at the views and experiences of patients and carers in using these drugs, and creating novel patient-defined outcome measures. This evidence was crucial in Alzheimer’s Society’s campaigning work against the decision of NICE. Person centred care as an alternative to antipsychotic medication The FITS (focused intervention in training and support demonstrated a 50% reduction in antipsychotic use in care homes. Alzheimer’s Society has now started a role out of this package across the UK.

Summary Research is what many donors and supporters of our organisation wish their money to be spent on. Research offers hope to patients and carers. Research raises awareness of dementia and the profile of our organisation. Research can innovate services and provide an evidence base to campaigns. Research always adds to knowledge, can train new leaders in the field and occasionally can provide the breakthroughs that we strive for. Thank you!